Technical Analysis for NGNE - Neurogene, Inc.

Grade Last Price % Change Price Change
F 15.33 -11.03% -1.90
NGNE closed down 11.03 percent on Wednesday, November 20, 2024, on 2.73 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other -11.03%
Lower Bollinger Band Walk Weakness -11.03%

   Recent Intraday Alerts

Alert Time
Down 10% about 16 hours ago
Possible NR7 about 16 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Up 1% about 19 hours ago
2x Volume Pace about 20 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Neurogene, Inc. Description

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Rare Diseases Gene Therapy Medical Genetics Genetic Engineering Central Nervous System Disorders Gene Delivery Molecular Genetics Neurological Diseases Transgene

Is NGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 74.49
52 Week Low 12.49
Average Volume 292,861
200-Day Moving Average 38.89
50-Day Moving Average 45.88
20-Day Moving Average 46.54
10-Day Moving Average 41.50
Average True Range 6.83
RSI (14) 26.47
ADX 30.56
+DI 22.02
-DI 48.12
Chandelier Exit (Long, 3 ATRs) 54.01
Chandelier Exit (Short, 3 ATRs) 35.76
Upper Bollinger Bands 79.64
Lower Bollinger Band 13.44
Percent B (%b) 0.03
BandWidth 142.26
MACD Line -6.57
MACD Signal Line -1.33
MACD Histogram -5.237
Fundamentals Value
Market Cap 196.59 Million
Num Shares 12.8 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.59
Resistance 3 (R3) 18.93 18.19 18.04
Resistance 2 (R2) 18.19 17.36 18.02 17.86
Resistance 1 (R1) 16.76 16.85 16.39 16.42 17.68
Pivot Point 16.02 16.02 15.84 15.85 16.02
Support 1 (S1) 14.59 15.19 14.22 14.25 12.98
Support 2 (S2) 13.85 14.68 13.68 12.80
Support 3 (S3) 12.42 13.85 12.62
Support 4 (S4) 12.08